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Introduction: Pseudomonas aeruginosa nosocomial pneumonia (Pa-NP) is associated with considerable morbidity,
prolonged hospitalization, increased costs, and mortality.
Methods: We conducted a retrospective cohort study of adult patients with Pa-NP to determine 1) risk factors for
multidrug-resistant (MDR) strains and 2) whether MDR increases the risk for hospital death. Twelve hospitals in 5
countries (United States, n = 3; France, n = 2; Germany, n = 2; Italy, n = 2; and Spain, n = 3) participated. We
compared characteristics of patients who had MDR strains to those who did not and derived regression models to
identify predictors of MDR and hospital mortality.
Results: Of 740 patients with Pa-NP, 226 patients (30.5%) were infected with MDR strains. In multivariable analyses,
independent predictors of multidrug-resistance included decreasing age (adjusted odds ratio [AOR] 0.91, 95%
confidence interval [CI] 0.96-0.98), diabetes mellitus (AOR 1.90, 95% CI 1.21-3.00) and ICU admission (AOR 1.73, 95%
CI 1.06-2.81). Multidrug-resistance, heart failure, increasing age, mechanical ventilation, and bacteremia were
independently associated with in-hospital mortality in the Cox Proportional Hazards Model analysis.
Conclusions: Among patients with Pa-NP the presence of infection with a MDR strain is associated with increased
in-hospital mortality. Identification of patients at risk of MDR Pa-NP could facilitate appropriate empiric antibiotic
decisions that in turn could lead to improved hospital survival.Introduction
Recent trends show an increase in the prevalence of noso-
comial pneumonia (NP) caused by multidrug-resistant
(MDR) Gram-negative bacteria, most commonly Pseudo-
monas aeruginosa with documented resistance to β-lactams,
carbapenems, aminoglycosides, and fluoroquinolones [1-3].
Consequently, the therapeutic effectiveness of current
therapies for bacterial NP is becoming increasingly lim-
ited, emphasizing the need for development of new and
effective antimicrobials as well as novel strategies to pre-
vent resistance emergence [4,5].* Correspondence: scott.micek@stlcop.edu
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unless otherwise stated.Nosocomial pneumonia due to P. aeruginosa (Pa-NP)
is associated with considerable morbidity, prolonged
hospitalization, increased costs, and mortality [6-8]. P.
aeruginosa is one of the few pathogens independently
associated with increased mortality among patients with
sepsis or pneumonia in the ICU setting [6,9]. The mor-
tality associated with Pa-NP is further increased when
inappropriate initial antibiotic therapy (IIAT) is pre-
scribed, usually due to the presence of MDR pathogens
[10-13]. The overall impact of Pa-NP on clinical out-
comes and healthcare costs underscores the importance
of this nosocomial infection. Therefore, we performed a
multinational study with the following objectives: first,
to evaluate the prevalence of MDR Pa-NP and to iden-
tify clinical risk factors associated with MDR Pa-NP;This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tient outcomes.
Methods
Study design and ethical standards
We conducted a retrospective study in 12 hospitals in 5
countries (United States, n = 3; France, n = 2; Germany,
n = 2; Italy, n = 2; and Spain, n = 3). Eligible patients
were aged ≥18 years consecutively admitted for their
index hospitalization within 36 months prior to study
initiation in 2013. All eligible patients met a clinical
diagnosis of NP defined as new or progressive infiltrates
consistent with pneumonia on chest radiograph or com-
puted tomography and either a temperature >38.3°C or
leukocytosis >10,000 cells/mm3 or both. To be eligible,
patients had to have P. aeruginosa cultured from at least
one of the following respiratory specimens, including
sputum, pleural fluid, flexible bronchoscopy with pro-
tected specimen brush, bronchoalveolar (BAL), transbron-
chial biopsy, nonbronchoscopic BAL, or tracheobronchial
aspirate in intubated patients. Microbiologic cultures
(qualitative or quantitative) had to be obtained within the
12-hour window before or the 12-hour window after the
initiation of antibiotic(s) targeting P. aeruginosa. Each
investigator obtained approval and a waiver of patient
consent from an Independent Ethics Committee or Insti-
tutional Review Board at their institution before commen-
cing the study. The list of all ethical bodies that approved
the study can be found in the Acknowledgements section.
Endpoints and covariates
The primary endpoints examined were multidrug-resistance
and hospital mortality. We collected important covariates
including demographics, comorbidities (heart failure, dia-
betes mellitus, chronic obstructive pulmonary disease,
chronic kidney disease, chronic liver disease, hematologic
malignancy, solid tumor, HIV/AIDS, and dementia). In
addition, important process-of-care variables, including
ICU admission, mechanical ventilation, vasopressor ad-
ministration, and the appropriateness of initial antibiotic
therapy, were collected.
Definitions
To be classified as MDR, the P. aeruginosa isolate had
to be non-susceptible to one or more agents in three or
more of the following antimicrobial categories, as deter-
mined by the European Center for Disease Prevention
and Control (ECDC) and the Centers for Disease Control
and Prevention (CDC): aminoglycosides, antipseudomonal
carbapenems, antipseudomonal cephalosporins, antipseu-
domonal fluoroquinolones, antipseudomonal penicillins
plus β-lactamase inhibitors, monobactams, phosphonic
acids, and polymixins. To be classified as extensively
drug-resistant (XDR), the P. aeruginosa isolate had to benon-susceptible to one or more agents in all but two or
more of the aforementioned antimicrobial categories [14].
Antimicrobial treatment was deemed to be appropriate
(AIAT) if at least one of the initially prescribed antibiotics
was active against the identified P. aeruginosa isolate
based on in vitro susceptibility testing and this antibiotic
was administered within 24 hours after collection of the
respiratory specimen [15].
Antimicrobial susceptibility testing
Microbiology laboratories performed antimicrobial suscep-
tibility testing of isolates using disk diffusion or automated
testing methods according to guidelines and breakpoints
established by the Clinical Laboratory and Standards Insti-
tute (CLSI) [16] and the European Committee on Anti-
microbial Susceptibility Testing (EUCAST) [17].
Statistical analyses
Continuous variables were reported as means with
standard deviation or the median and interquartile range
from non-normally distributed data. Differences between
continuous variables were tested using Student’s t-test or
the nonparametric Mann-Whitney U-test. Categorical
data were summarized as proportions, and the Chi-
square test or Fisher’s exact test for small samples was
used to examine differences between groups. Univariate
and multivariate logistic regression models were con-
structed to identify clinical risk factors associated with
multidrug-resistance. All variables that showed a signifi-
cant result in the univariate analysis (≤0.10) were included
in the corresponding multivariate logistic regression ana-
lysis. All variables entered into the models were examined
to assess for co-linearity, and interaction terms were
tested. The model’s calibration was assessed with the
Hosmer-Lemeshow goodness-of-fit test. A Cox propor-
tional hazards model was constructed to determine vari-
ables independently associated with hospital mortality.
This test was selected to exclude the influence of time-
dependent covariates on hospital mortality and to ad-
equately control for imbalances in baseline and clinical
characteristics when constructing a survival curve. All
tests were two-tailed, and a P-value <0.05 was deemed a
priori to represent statistical significance. All analyses
were performed with SPSS software, version 19.0 (IBM
SPSS, Chicago, IL, USA).
Results
Seven hundred and forty patients with Pa-NP met the in-
clusion criteria and were enroled in the study: 258 (34.9%)
from the United States, 141 (19.1%) from France, 120
(16.2%) from Germany, 113 (15.3%) from Spain and 108
(14.6%) from Italy. The prevalence of multidrug resistance
was 30.5%. The patients’ baseline and clinical characteris-
tics are shown in Table 1. Patients with pneumonia caused









Age, years, mean ± SD 0.5%a 53.5 ± 17.5 62.1 ± 15.5 <0.001
Male 0% 142 (62.8%) 361 (70.2%) 0.047
Location prior to admission 1.1%
Community 101 (44.7%) 286 (55.6%) 0.006
Skilled nursing facility 17 (7.5%) 37 (7.2%) 0.876
Long-term care facility 7 (3.1%) 20 (3.9%) 0.596
Assisted living 4 (1.8%) 3 (0.6%) 0.125
Inpatient rehabilitation 27 (11.9%) 20 (3.9%) <0.001
Other 66 (29.2%) 144 (28.0%) 0.741
Past medical history
Hospitalized in the previous 6 months 13.1% 126 (60.6%) 245 (56.3%) 0.307
Antibiotics in the previous 30 days 27.6% 100 (57.5%) 163 (45.0%) 0.007
Heart failure 9.6% 49 (23.2%) 131 (28.6%) 0.145
Chronic obstructive pulmonary disease 9.2% 102 (48.8%) 173 (37.4%) 0.005
Diabetes mellitus 8.6% 79 (37.8%) 137 (29.3%) 0.029
Chronic kidney disease 9.3% 55 (26.3%) 118 (25.5%) 0.832
Chronic liver disease 11.9% 38 (18.5%) 70 (15.7%) 0.359
Hematologic malignancy 9.9% 20 (9.4%) 40 (8.8%) 0.807
Solid tumor 10.3% 18 (8.7%) 81 (17.7%) 0.002
HIV/AIDS 10.5% 3 (1.5%) 6 (1.3%) 0.885
Dementia 12.6% 6 (3.0%) 36 (8.1%) 0.015
Charlson score, mean ± SD 2.6% 3.1 ± 2.6 3.0 ± 2.6 0.869
Pneumonia category 0%
Community-onset, healthcare-associated 74 (32.7%) 167 (32.5%) 0.946
Hospital-onset 152 (67.2%) 347 (67.5%) 0.946
Hospital-acquired 50 (22.1%) 112 (21.8%) 0.919
Ventilator-associated 102 (45.1%) 235 (45.7%) 0.883
ICU admission 0% 180 (79.6%) 367 (71.4%) 0.019
Length of ICU stay, days, median (IQR) 0% 18.9 (11.4, 32.5) 16.1 (8.7, 29.1) 0.058
Mechanical ventilation 0% 197 (87.2%) 440 (85.6%) 0.571
Length of mechanical ventilation, days, median (IQR) 0% 17.0 (9.1, 34.1) 13.1 (6.5, 26.0) 0.006
Vasopressor administration 0% 146 (64.6%) 308 (59.9%) 0.229
Bacteremia 0% 53 (23.5%) 128 (24.9%) 0.672
Inappropriate initial antibiotic therapy 1.5% 83 (37.9%) 98 (19.2%) <0.001
In-hospital mortality 0% 101 (44.7%) 163 (31.7%) 0.001
Length of hospital stay, days, median (IQR) 0% 27.0 (14.0, 56.3) 25.0 (13.0, 46.0) 0.090
aFour patients aged >90 years (one MDR, three non-MDR) were not included in the calculation.
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ger and were more likely to be admitted to the hospital
from an inpatient rehabilitation facility compared to pa-
tients infected with non-MDR strains. Patients with MDR
strains were significantly more likely to have received anti-
biotics in the 30 days prior to the diagnosis of pneumoniaand were also more likely to have chronic obstructive pul-
monary disease and diabetes mellitus. A significantly higher
proportion of patients who were infected with an MDR
strain received IIAT (37.9% versus 19.2%, P <0.001) and
required ICU admission (79.6% versus 71.4%, P = 0.019)
compared to those with a non-MDR strain.
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nificantly lower in patients infected with MDR strains
(Table 2). Antibiotic susceptibility by country is found in
Table 3. Germany (44.2%) and Spain (43.4%) were found
to have the highest prevalence of MDR, followed by
France (33.3%), Italy (22.2%) and the United States
(20.5%). Table 4 shows the results of a multivariable lo-
gistic regression model that identified the variables asso-
ciated with pneumonia caused by MDR strains of P.
aeruginosa. Decreasing age in increments of one year,
diabetes mellitus, and ICU admission were independ-
ently associated with MDR P. aeruginosa pneumonia.
The overall, hospital mortality was 35.7% (n = 264).
Mortality was significantly different between the United
States and European countries: United States, 22.5%;
France, 37.6%; Germany, 41.7%; Spain, 46.9%; and Italy,
46.3%. Patients with MDR strains had a significantly
higher in-hospital mortality rate compared to non-MDR
infected patients (Table 1). A Cox proportional hazards
model confirmed MDR status as an independent pre-
dictor of mortality (hazard ratio (HR) 1.39, 95% CI 1.05
to 1.83, P = 0.021) along with increasing age, heart failure,
concomitant bacteremia, mechanical ventilation, and pa-
tients residing in Germany, Italy, and Spain (Table 5). Cox
model-adjusted survival curve analysis controlling baseline
and clinical imbalances confirmed the influence of MDR
on in-hospital mortality (Figure 1).
Discussion
This international investigation representing the largest
cohort study of Pa-NP demonstrated high prevalence of
MDR at 30.5%. Infection caused by MDR P. aeruginosa
was found to be an important determinant of hospital
mortality, thus, it is critical for clinicians to identify pa-
tients at risk of MDR from the onset of infection. Our
analysis suggests that the patient’s age, comorbid condi-
tions specifically diabetes, and the severity of infection
as indicated by the need for ICU admission predicts in-




Antipseudomonal carbapenems 226 (15.0%)
Antipseudomonal cephalosporins 226 (26.5%)
Antipseudomonal fluoroquinolones 222 (21.5%)
Antipseudomonal penicillins + 221 (22.2%)
β-lactamase inhibitors
Monobactams 158 (13.9%)
Phosphonic acids 86 (40.7%)
Polymyxins 159 (97.5%)
Data presented as number of isolates tested (% susceptible). Multidrug-resistant: noThe prevalence of MDR Pa-NP is variable depending
on the type of study performed and the participating in-
stitutions. A recent large epidemiologic study from the
United States identified 205,526 P. aeruginosa isolates
(187,343 pneumonia; 18,183 bloodstream infection (BSI))
and 95,566 Enterobacteriaceae specimens (58,810 pneu-
monia; 36,756 BSI) associated with infection [1]. Preva-
lence of MDR P. aeruginosa (MDR Pa) was approximately
15-fold greater than carbapenem-resistant-Enterobacteria-
ceae in both infection types. A net rise in MDR Pa as a
proportion of all P. aeruginosa infections occurred from
2000 to 2009. Likewise, data from the National Healthcare
Safety Network (NHSN) in the United States revealed an
increased prevalence of MDR Pa VAP from the period
2007 to 2008 to the period 2009 to 2010, but, it should be
noted the overall prevalence of MDR Pa was 17.7% in the
latter time period, markedly less than our study [3]. The
international composition of the participants is the most
likely explanation for the higher prevalence of MDR
strains in our study.
The literature also varies with respect to the outcomes
of patients with MDR Pa-NP. Peña et al. examined a
Spanish cohort of 91 episodes of ventilator-associated
pneumonia (VAP) in 83 patients, 31 caused by suscep-
tible P. aeruginosa and 60 by MDR Pa strains [18].
These investigators found that susceptible P. aeruginosa
infections were more likely than MDR Pa episodes to re-
ceive AIAT and definitive antimicrobial therapy, and in a
logistic regression model IIAT was identified as an inde-
pendent risk factor for early mortality. A recent meta-
analysis supports these findings by demonstrating that
MDR status is an important determinant of mortality due
to nosocomial infections attributed to Gram-negative bac-
teria, where P. aeruginosa and Acinetobacter species were
the most common isolates [19]. Di Pasquale et al. recently
found MDR status was not associated with a higher rate of
ICU or hospital mortality in patients with ICU-acquired
pneumonia. However, unlike our study, the etiology of in-











n-susceptible to one or more agents in three or more antibiotic classes.
Table 3 Antibiotic susceptibility by country
Antibiotic class France Germany Italy Spain United States
Aminoglycosides 141(76.6) 120 (58.3) 101 (75.2) 112 (58.9) 257 (80.2)
Antipseudomonal carbapenems 139 (60.4) 119 (52.1) 107 (57.9) 112 (47.3) 257 (79.0)
Antipseudomonal cephalosporins 140 (77.1) 120 (60.8) 101 (74.3) 111 (59.5) 258 (81.4)
Antipseudomonal fluoroquinolones 138 (66.7) 118 (61.0) 100 (75.0) 111 (52.3) 257 (75.9)
Antipseudomonal penicillins + 141 (64.5) 118 (46.5) 108 (70.3) 110 (63.6) 253 (82.6)
β-lactamase inhibitors
Multidrug-resistant 141 (33.3) 120 (44.2) 108 (22.2) 113 (43.4) 258 (20.5)
Extensively drug-resistant 141 (17.7) 120 (34.2) 108 (2.8) 113 (13.3) 258 (3.5)
Data presented as number of isolates tested (% susceptible). Multidrug-resistant: non-susceptible to one or more agents in three or more antibiotic classes.
Extensively drug-resistant: non-susceptible to one or more agents in all but two or fewer antibiotic classes.
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cases (n = 18) [20].
Increasing antimicrobial resistance in P. aeruginosa
infections seems to be the most important predictor of
outcome. In a recent Brazilian study of P. aeruginosa
bacteremia isolates from 120 patients [21], 45.8% were re-
sistant to carbapenems, and 23.3% expressed a metallo-β-
lactamase gene, blaSPM-1 (57%) or blaVIM-type (43%).
Cefepime-resistance, MDR status and XDR isolates were
independently associated with IIAT, which was an import-
ant predictor of mortality. These studies support the im-
portance of appropriate and timely antibiotic therapy as a
potential determinant of outcome for serious infections at-
tributed to P. aeruginosa. Given the association of anti-
biotic resistance with increasing administration of IIAT
and greater hospital mortality, several strategies have been
developed to improve upon the appropriateness of empiric
therapy in patients at risk of infection with P. aeruginosa
and other antibiotic-resistant pathogens.
A number of investigations have identified risk factors
and scoring systems for infection with MDR pathogens,




Age (decreasing increments of 1) 0.97
Male 0.72
Residence in a community setting prior to admission 0.64
Residence in an inpatient rehabilitation facility prior to admission 3.35
Antibiotics in the previous 30 days 1.65





aHosmer-Lemeshow goodness-of-fit test, P = 0.72.approaches are that the potential for IIAT remains, al-
though potentially diminished, and the resultant overuse
of broad-spectrum antibiotics in many patients because of
the non-specificity of the scoring systems. Novel methods
to improve early identification of pathogens and antibiotic
susceptibilities are also entering the diagnostic arena. Such
diagnostic technology advances offer the potential to
maximize administration of appropriate antibiotic therapy
while minimizing unnecessary antibiotic exposure. These
approaches include the use of molecular methods (for ex-
ample, polymerase chain reaction electrospray ionization
mass spectrometry and matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF), as well as ad-
vanced automated microscopy techniques that allow the
identification of bacterial species, the presence of anti-
biotic resistance genes, and bacterial killing by specific
antibiotics within 4 to 6 hours using direct specimen in-
oculation [26,27].
Our study has a number of limitations. As a retrospect-
ive cohort, it is prone to several forms of bias, most not-
ably selection bias. We attempted to mitigate this by
enroling consecutive patients fitting the predeterminedsion analysis of predictors for multidrug-resistant (MDR)
ariate Multivariatea
ratio (95% CI) P-value Odds ratio (95% CI) P-value






(1.04, 2.06) 0.030 1.90 (1.21, 3.00) 0.006
(0.26, 0.76) 0.003
(0.15, 0.85) 0.020
(1.08, 2.28) 0.019 1.73 (1.06, 2.81) 0.028
Table 5 Cox proportional hazards model of significant




Heart failure 1.88 (1.39, 2.52) <0.001
Age (increasing increments of 1 year) 1.02 (1.01, 1.03) 0.001
Country of origin, Germany 3.05 (1.87, 4.96) <0.001
Country of origin, Italy 2.38 (1.41, 4.02) 0.001
Country of origin, Spain 1.91 (1.16, 3.14) 0.011
Mechanical ventilation 1.88 (1.02, 3.48) 0.044
Bacteremia 1.67 (1.20, 2.31) 0.002
Multidrug resistance 1.39 (1.05, 1.83) 0.021
No vasopressors 0.61 (0.43, 0.87) 0.006
Healthcare associated pneumonia 0.50 (0.35, 0.73) <0.001
Variables excluded from the model for co-linearity: aminoglycoside resistance,
carbapenem resistance, fluoroquinolone resistance, penicillin-β-lactamase
inhibitor resistance (co-linear with multidrug resistance); country of origin -
United States (co-linear with France, Germany, Italy, and Spain). Variables
included but not retained in the model at P <0.05: ICU admission, chronic
kidney disease, chronic liver disease, country of origin - France.
Figure 1 Cox proportional hazards model curve comparing patients with m
non-MDR P. aeruginosa nosocomial pneumonia.
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founders, the possibility exists that some residual con-
founding remains, particularly confounding by indication.
Another important limitation is the potential for patients
to be enroled who did not have true pneumonia. Our use
of clinical criteria along with microbiologic confirmation
was an attempt to maximize the number of patients with
Pa-NP in our cohort. Additionally, antimicrobial suscepti-
bility testing was performed at the local hospital level.
Therefore, the determination of MDR status may have
varied more than if a single reference laboratory was used
to determine the presence or absence of drug resistance. It
is also important to note that although our results strongly
suggest that the association ofMDR status with increased risk
of death is mechanistically related to the risk of receiving in-
appropriate empiric therapy, we cannot rule out that MDR
Pa-NP may exert its lethal effect directly due to higher viru-
lence, as has been suggested with other pathogens exhibiting
higher minimum inhibitory concentration (MIC) to certain
antimicrobials [28,29]. Because we examined hospital mortal-
ity rather than the more standard 28-day mortality as the pri-
mary outcome for our study, we may have overestimated the
magnitude of this outcome. Last, individual antibiotics
are commonly part of a regimen for the treatment ofultidrug-resistant (MDR)-Pseudomonas aeruginosa and those with
Micek et al. Critical Care  (2015) 19:219 Page 7 of 8nosocomial pneumonia, therefore, independent analysis
of the impact on AIAT may not represent the true pre-
scribing practice at each site.
Conclusions
In summary, our study sheds light on variables associ-
ated with to MDR Pa-NP; namely decreasing age, dia-
betes mellitus and ICU admission. In addition, MDR
status is an independent predictor of hospital mortality
in patients with Pa-NP. Given the high rates of MDR
Pa-NP, advances in rapid diagnosis and susceptibility
analysis are needed to direct antibiotic treatment and
potentially improve outcomes.
Key messages
 Among patients with Pa-NP, presence of infection
with MDR strains is an important independent
predictor for hospital mortality.
 Independent predictors of MDR strains of
P. aeruginosa in this study included decreasing age,
diabetes, and ICU admission.
 Advances in rapid diagnostics and antibiotic
susceptibility analysis are needed to direct antibiotic
treatment and potentially improve outcomes of
patients infected with MDR strains of P. aeruginosa.
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